PFEPfizerSigning up patients
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
ACUTE LYMPHOBLASTIC LEUKEMIA
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- May 17, 2023
- Main results expected
- May 21, 2033
- Fully finished
- May 25, 2036
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Minimum Residual Disease (MRD) Negativity in participants achieving complete response (CR), complete response with incomplete platelet count recovery (CRp), or complete response with incomplete count recovery (CRi)
Measured over: After 1 treatment cycle: Day 28 +/- 2 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05748171 · record last updated 2026-09-24 · checked 2026-11-09 15:42 UTC